Aligos Therapeutics, Inc. (ALGS)
NASDAQ: ALGS · IEX Real-Time Price · USD
0.504
+0.011 (2.17%)
At close: Jul 19, 2024, 4:00 PM
0.503
-0.001 (-0.14%)
Pre-market: Jul 22, 2024, 6:06 AM EDT

Aligos Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Year Ending
TTM Dec 31, 2023Dec 31, 2022Dec 31, 2021Dec 31, 2020Dec 31, 2019 2018
Revenue
13.7915.5313.914.3600
Upgrade
Revenue Growth (YoY)
-1.90%11.66%219.04%---
Upgrade
Gross Profit
13.7915.5313.914.3600
Upgrade
Selling, General & Admin
28.7830.6226.4128.5317.9410.01
Upgrade
Research & Development
71.2773.0485.08104.1579.8944.04
Upgrade
Operating Expenses
100.05103.66111.49132.6897.8354.04
Upgrade
Operating Income
-86.26-88.13-97.58-128.32-97.83-54.04
Upgrade
Interest Expense / Income
12.55-1.24-1.64-0.1310.55-1.86
Upgrade
Pretax Income
-98.81-86.88-95.94-128.19-108.38-52.18
Upgrade
Income Tax
0.780.80.110.140.160.09
Upgrade
Net Income
-99.59-87.68-96.05-128.33-108.54-52.26
Upgrade
Shares Outstanding (Basic)
156644340102
Upgrade
Shares Outstanding (Diluted)
156644340102
Upgrade
Shares Change
263.91%50.51%7.13%299.03%397.62%-81.93%
Upgrade
EPS (Basic)
-1.04-1.36-2.25-3.22-10.87-26.04
Upgrade
EPS (Diluted)
-1.04-1.36-2.25-3.22-10.87-26.04
Upgrade
Free Cash Flow
-79.44-79.02-80.33-116.55-76.33-49.55
Upgrade
Free Cash Flow Per Share
-0.51-1.23-1.88-2.92-7.64-24.69
Upgrade
Gross Margin
100.00%100.00%100.00%100.00%--
Upgrade
Operating Margin
-625.40%-567.50%-701.66%-2943.82%--
Upgrade
Profit Margin
-722.06%-564.61%-690.63%-2944.07%--
Upgrade
Free Cash Flow Margin
-575.96%-508.83%-577.64%-2673.87%--
Upgrade
EBITDA
-83.36-85.06-93.91-124.54-94.51-51.74
Upgrade
EBITDA Margin
-604.38%-547.74%-675.24%-2857.15%--
Upgrade
Depreciation & Amortization
2.93.073.683.783.332.3
Upgrade
EBIT
-86.26-88.13-97.58-128.32-97.83-54.04
Upgrade
EBIT Margin
-625.40%-567.50%-701.66%-2943.82%--
Upgrade
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).